MIM
LABP

Monashee Investment Management’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Monashee Investment Management’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-9,131
Closed -$879K – 507
2021
Q1 		$879K Buy
+9,131
New +$1.19M 0.14% 192

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Monashee Investment Management's LABP Position: Q2 2021 in Review

Monashee Investment Management sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2021, closing a stake of 9,131 shares — an estimated $879K sold.

Monashee Investment Management first reported a position in LABP in Q1 2021 and held it in 1 quarter. The position peaked at $879K in Q1 2021. 33 funds tracked by Wall St. Rank hold LABP as of Q2 2021.

  • Monashee Investment Management reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Monashee Investment Management sold 9,131 Landos Biopharma, Inc. Common Stock shares in Q2 2021, an estimated $879K.
  • Monashee Investment Management first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Monashee Investment Management's Landos Biopharma, Inc. Common Stock position peaked at $879K in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2021.

Based on Monashee Investment Management's 13F filing for Q2 2021, filed 12 Aug 2021.